Stakeholder Opinions: Vaccine administration technologies - Beyond needles

Table of Contents

EXECUTIVE SUMMARY

• Strategic scoping and focus
• Datamonitor insight into the vaccine administration market
• Related reports
• Upcoming related reports

BRIEF HISTORY OF THE DEVELOPMENT OF VACCINE ADMINISTRATION SYSTEMS

• Overview of past developments in the vaccine administration sector

RATIONALE FOR THE DEVELOPMENT OF NOVEL VACCINE ADMINISTRATION SYSTEMS

• Unmet needs regarding vaccine administration differ between the developed and the developing world
• Vaccine delivery through needle / syringe injection is associated with considerable health risks
• Alternative vaccine delivery technologies could provide better protection through a combined mucosal / systemic immune response
• Compliance could be improved through painless delivery alternatives
• Alternative delivery technologies could reduce or eliminate the need for a cold chain
• Increased ease of use and speed of vaccine delivery is a key achievable for biodefense indications and mass vaccination campaigns
• From a marketing perspective, vaccine administration could become an advantage in highly competitive segments of the vaccines market

CHALLENGES FOR NOVEL VACCINE ADMINISTRATION SYSTEMS

• The regulatory pathway for novel delivery systems is complicated
• The oligopoly structure of the vaccines market and the decreasing funding for biotech companies as a result of the economic downturn represent further challenges
• The limited knowledge of the molecular mechanisms linked to vaccine administration hampers the development of new technologies
• Cost constraints could dent the commercial opportunity of novel vaccine administration systems
• Various new technologies are currently in development for vaccine administration

DERMAL VACCINE ADMINISTRATION

• Transdermal vaccine delivery
  • General considerations
  • Transdermal vaccine delivery systems

• Transdermal patches
  • Key transdermal patch systems in development for vaccine administration
  • Datamonitor assessment

• Microneedles
  • Key microneedle-based systems in development for vaccine administration
  • Datamonitor assessment

• Needle-free solid, liquid or powder injection technologies
  • General considerations
  • Key needle-free injection systems in development for vaccine administration
  • Datamonitor assessment

MUCOSAL VACCINE ADMINISTRATION

• Oral vaccine delivery
  • General considerations
  • Oral vaccine delivery systems
  • Marketed and pipeline oral vaccines
  • Datamonitor assessment

• Intranasal vaccine delivery
  • General considerations
  • Intranasal vaccine delivery systems
  • Marketed and pipeline intranasal vaccines
  • Datamonitor assessment

• Pulmonary vaccine delivery
  • General considerations
  • Pulmonary vaccine delivery systems
  • Marketed and pipeline pulmonary vaccines
  • Datamonitor assessment

BIBLIOGRAPHY

• Literature

APPENDIX

• Contributing experts
  • Academic key opinion leaders
  • Industry key opinion leaders
  • Conferences

• Report methodology

TABLES

• Table: Summary of key vaccine administration technologies in development, 2009
• Table: Key transdermal patch technologies in active development for vaccines, 2009
• Table: SWOT analysis - transdermal patch vaccine delivery systems
• Table: Key microneedle technologies in active development for vaccines
• Table: SWOT analysis - microneedle vaccine delivery systems
• Table: Key needle-free injector technologies in active development for vaccines
• Table: SWOT analysis - needle-free injection vaccine delivery systems
• Table: Key marketed oral vaccines, April 2009
• Table: Key oral pipeline vaccines, April 2009
• Table: SWOT analysis - oral vaccine delivery systems
• Table: Key marketed and pipeline nasal vaccines, March 2009
• Table: SWOT analysis - nasal vaccine delivery systems, 2009
• Table: Comparison of different classes of pulmonary inhaler devices
• Table: Key pipeline pulmonary vaccines, March 2009
• Table: SWOT analysis - pulmonary vaccine delivery systems

FIGURES

• Figure: Key events in the history of vaccine administration
• Figure: Unmet needs in vaccine administration in the developed and developing worlds
• Figure: Drivers and resistors for vaccine administration technology development
• Figure: Overview of the development stage and expected market entry of key physical vaccine delivery technologies, 2009- 2019
• Figure: Transdermal vaccine delivery
• Figure: Transdermal patch vaccine delivery
• Figure: Microneedle vaccine delivery
• Figure: Becton Dickinson - BD Soluvia
• Figure: 3M Drug Delivery Systems - Solid Microstructured Transdermal System
• Figure: Nanopass - MicroPyramids
• Figure: Zosano Pharma' s ZP patch technology
• Figure: Needle-free injector vaccine delivery
• Figure: Glide Pharma' s Glide SDI
• Figure: PharmaJet' s liquid jet injector
• Figure: Mucosa-associated lymphoid tissue and aggregates
• Figure: Generation of immunity through mucosal vaccination
• Figure: Advantages and drawbacks of mucosal vaccination
• Figure: Annual sales of RotaTeq versus Rotarix, 2006- 08
• Figure: FluMist - vaccine sales in the US, 2004- 08
• Figure: FluMist - CDC and private sector costs/dose in the US, 2004- 08